Wedbush Reaffirms "Outperform" Rating for Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "outperform" rating reaffirmed by investment analysts at Wedbush in a note issued to investors on Wednesday, Marketbeat.com reports. They currently have a $11.00 price objective on the stock. Wedbush's price objective would suggest a potential upside of 400.00% from the company's current price.

CATX has been the subject of a number of other reports. Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Royal Bank of Canada reissued an "outperform" rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 19th. Finally, Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $14.44.

Perspective Therapeutics Stock Down 4.3 %

Perspective Therapeutics stock traded down $0.10 on Wednesday, reaching $2.20. 657,194 shares of the stock were exchanged, compared to its average volume of 999,856. Perspective Therapeutics has a twelve month low of $2.19 and a twelve month high of $19.05. The firm has a fifty day moving average price of $2.94 and a two-hundred day moving average price of $6.29.

Remove Ads

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at approximately $33,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $34,000. National Bank of Canada FI raised its position in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after acquiring an additional 10,998 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after acquiring an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. bought a new position in Perspective Therapeutics in the fourth quarter valued at about $51,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.